Wedbush reiterated their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has a $41.00 price target on the stock. Other analysts also recently issued reports about the stock. Jefferies Financial Group initiated coverage on shares of Aerovate Therapeutics in […]
Wedbush restated their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a $41.00 price target on the stock. AVTE has been the subject of a number of other reports. Wells Fargo & Company reissued an overweight rating and […]
21.05.2024 - Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally . Seite 1
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.